Pharmaceuticals News & Press Release Distribution

Pharmaceuticals

APAC
Global

RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias

The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world's first circular RNA-based in vivo CAR-T therapy achieving FDA IND clearance. RiboX e...

2026-08-08 15:46 4545

Alebund's AP301 NDA Accepted for Review by China's NMPA

SHANGHAI, Aug. 7, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that the New Drug Application (NDA) for AP301 capsules, a novel oral iron-based phosphate binder, for the treatmen...

2026-08-07 18:40 3501

Yochanra®, the World's First Innovative Drug to Overcome FGFR Inhibitor Resistance, Makes Its Global Debut in China

NANJING, China and GAITHERSBURG, Md., Aug. 7, 2026 /PRNewswire/ -- TransThera Sciences' Yochanra® is the first drug independently developed in China to address the longstanding global challenge of acquired resistance to FGFR inhibitor therapy in patients with cholangiocarcinoma. On 6 August 2026,...

2026-08-07 14:44 4155

Ractigen Therapeutics Announces Completion of Enrollment and First Dosing in Phase II Clinical Trial of RAG-17 for SOD1-ALS

NANTONG, China, Aug. 6, 2026 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics, today announced the completion of patient enrollment and initial dosing across all cohorts in its Phase II clinical trial evaluating RAG-17, an ...

2026-08-06 19:30 2546

Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq

SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Attovia Therapeutics, a portfolio company of Qiming Venture Partners and clinical-stage biopharmaceutical leader, successfully listed on the Nasdaq on August 5, 2026 Beijing time. Attovia Therapeutics (Nasdaq: ATTO) issued shares at a price of $17.00 per sha...

2026-08-06 18:46 4226

Harbour BioMed Appoints Dr. Bob Zhang as President of Metabolic Disease Franchise to Accelerate Global Development of Innovative Therapies

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment ...

2026-08-06 16:10 3237

Clarivate Scales Agentic AI Across Cortellis to Advance Drug Development

Expanded capabilities across Cortellis portfolio help life sciences organizations turn trusted intelligence into action and accelerate decision making across the research and development lifecycle LONDON, Aug. 6, 2026 /PRNewswire/ -- Clarivate Plc

2026-08-06 16:00 1565

Fosun International Wins Three Awards from Global Banking & Finance Review, Gaining International Recognition for its ESG Performance, Corporate Social Responsibility, and Brand Strength

HONG KONG, Aug. 6, 2026 /PRNewswire/ -- Recently, Global Banking and Finance Review, a leading British financial magazine, announced its 2026 award winners. Fosun International Limited (HKEX stock code: 00656) received three awards in recognition of its outstanding contributions to sustainable de...

2026-08-06 13:17 6059

Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China

SAN FRANCISCO and SUZHOU, China, Aug. 5, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...

2026-08-06 08:00 4644

Telix to Host R&D Day in New York City on September 22, 2026

MELBOURNE, Australia and INDIANAPOLIS, Aug. 6, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that it will host a Research and Development (R&D) Day on Tuesday, September 22, 2026, from 8:30 a.m. to 12:30 p.m. EDT in New York City. Institutional...

2026-08-06 05:00 2980

Nearly 3 in 10 Veterinarians at Japan's Larger Companion-Animal Hospitals Say Their Current Pace Is Unsustainable, Zpeer Survey Finds

TOKYO, August 5, 2026 /PRNewswire/ -- Zpeer Inc., operator of Vetpeer — Japan's largest online community for veterinary professionals, reaching approximately 80% of the country's small-animal veterinarians —today released the results of a survey of 314 companion-animal veterinarians on their work...

2026-08-05 21:00 3100

Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization

CRANBURY, N.J. and SUZHOU,China, Aug. 5, 2026 /PRNewswire/ -- Recently, Porton Advanced Solutions Ltd. ("Porton Advanced") has officially been granted a Drug Manufacturing License (Class C) by the National Medical Products Administration (NMPA).This milestone qualifies Porton Advanced to undertak...

2026-08-05 20:00 2234

Alteogen Announces Exclusive License Agreement with a Global Pharmaceutical Company for the Development and Commercialization of a Hybrozyme™-Enabled Subcutaneous Biologic Product

* Alteogen grants exclusive rights to develop and commercialize a subcutaneous biologic product using Hybrozyme™-based hyaluronidase ALT-B4 * Alteogen is eligible to receive up to US$365 million, including an upfront payment and development, regulatory and sales milestone payments * Addition...

2026-08-05 20:00 2622

Leading the Future of Oral Delivery, Lonza Capsugel brings breakthrough Capsule Technologies to the Korean Market at CPHI Korea

Advanced Capsule Technology for Improved Digestive Enzyme Delivery SEOUL, South Korea, Aug. 5, 2026 /PRNewswire/ -- Lonza Capsugel has released new peer-reviewed research showing that its Licaps® DUOCAP® capsule-in-capsule technology can significantly improve the protection and targeted deliv...

2026-08-05 18:39 3416

Leading the Future of Oral Delivery, Lonza Capsugel brings breakthrough Capsule Technologies to the Korean Market at CPHI Korea

Everest Medicines to Announce 2026 Interim Results and Host Online Investor Call on August 19, 2026

SHANGHAI, Aug. 5, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its interim result...

2026-08-05 17:37 2587

Sisram Medical Launches Titanium Prime Treatment Concept in Hong Kong SAR

Harnessing dual-device synergies, multi-energy technologies, and pioneering layered protocols, Sisram cements its strategic leadership across APAC HONG KONG, Aug. 5, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK), a global wellness group offering Energy-Based Devices...

2026-08-05 12:11 2624

NIPRO Launches Expanded Hemodialysis with ELISIO™-HX to U.S. Providers Following FDA Clearance

Now commercially available, the medium cut-off dialyzer expands access to enhanced middle molecule removal through existing dialysis infrastructure OSAKA, Japan and BRIDGEWATER, N.J., Aug. 4, 2026 /PRNewswire/ -- NIPRO CORPORATION, through its U.S.-based subsidiary Nipro Medical Corporation, toda...

2026-08-04 22:01 2765

72 patient multi-indication trial approved to fast track TRP-8803 commercialisation

* Human Research Ethics Committee (HREC) approval secured for world-first phase 1b/2a 8-indication basket study across in 72-patients of TRP-8803 * Study will evaluate TRP-8803 (IV-infused psilocin) across eight major disorders with high unmet treatment needs in a single clinical framework *...

2026-08-04 22:00 2944

AsymBio Secures US$184 Million Capital Injection to Support Long-Term Growth

SHANGHAI, Aug. 4, 2026 /PRNewswire/ -- AsymBio , a biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary ofAsymchem Group (stock codes: 002821.SZ / 6821.HK), today announced a total capital injection of ...

2026-08-04 20:30 4269

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deplo...

2026-08-04 18:15 2576

1 ... 14 15 161718 19 20 ... 348